Pelicluster CD41, 1ml

This monoclonal mouse antibody is a useful marker for studies of megakaryoblasts and megakaryoblastic leukaemias.

Article number M1538
Product group Monoclonal mouse antibody
Technique Indirect immunofluorescence staining with analysis by flow cytometry or fluorescence microscopy.

General information

This monoclonal antibody was created by fusing SP2/0 cells with spleen cells from a BALB/c mouse that had been immunized with human platelets. It was tested against CD41a in the Third, Fourth, and Sixth International Workshops on Human Leukocyte Differentiation Antigens. The antibody was isolated from the culture supernatant using affinity chromatography.

Under reducing conditions, the molecular masses observed are as follows: GPIIIa at 110 kDa; GPIIb alpha chain at 125 kDa; and GPIIb beta chain at 25 kDa.

The monoclonal mouse antibody is designed to target specific components of the blood clotting system. and targets megakaryocytes and platelets, specifically recognizing the intact thrombocyte GPIIb/IIIa complex. It does not interact with dissociated GPIIb or GPIIIa. Furthermore, it does not bind to thrombocytes from patients with Glanzmann’s thrombasthenia, nor does it recognize the vitronectin receptor, which involves GPIIa as a beta subunit (refer to CD61).

Product information

Pelicluster CD41, 1ml

Monoclonal/ Polyclonal: Monoclonal

Clone: CLB-tromb/7, 6C9

Host: Mouse

Isotype: IgG1

Application: Flow cytometry (FC)

Application notes: The monoclonal mouse antibody is a useful marker for studies of megakaryoblasts and megakaryoblastic leukaemias. Method: Indirect immunofluorescence staining with analysis by flow cytometry or fluorescence microscopy.

Conjugation Type: Conjugated

Conjugate: FITC

Conjugation note: FITC conjugated Goat anti-Mouse immunoglobulin antiserum, solid phase adsorbed with human immunoglobulins or comparable product. Remove aggregates by centrifugation at 1000 x g for 10 minutes. Dilute as mentioned in the procedure.

Purified: YES

Purification note: Culture supernatant purified by affinity chromatography.

Buffer: Wash- and dilution buffer for mononuclear cells,(PBS/BSA): Phosphate Buffered Saline containing 0.2% BSA (w/v). Wash- and dilution buffer for platelets, (Seq). Sequestrine buffer, storage 1 month at 2-8°C. 10 x stock solution…

Storage and Safety.

For in vitro diagnostic use only. Reagents should be stored at 2–8°C. Leaking or damaged vials must not be used. Reagents (unopened or opened) should not be used beyond the expiration date, which is printed on the label of the vial. The reagent cannot be assumed to be free from infectious agents.

Wash hands thoroughly after handling. Wear protective gloves/protective clothing/eye protection/face protection.

Care must be taken in the use and disposal of each container and its contents. Waste-disposal, after completion of the test, should be performed according to your laboratory regulations.

Causes serious eye irritation. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: get medical advice/attention. Absorb spillage to prevent material damage.

Package contents

– The flat-bottom microtiter plate consists of 12 strips of 8 wells ready for use. All the wells are coated with TNF-specific mouse monoclonal antibody and recombinant TNF. The microtiter plate is vacuum sealed in a plastic pouch containing desiccant. The kit provides the flexibility to use the microtiter plate on separate occasions. Determine the number of strips required to test the desired number of samples plus 8 wells needed for running calibrators and controls. Remove strips that will not be used from the microtiter plate-frame and re-pack them in the plastic pouch containing the desiccant.
– After opening, all reagents and the microtiter plate strips may be used for ≤ 6 weeks if stored at 2–8 °C.
– Consult the enclosed information leaflet for the kit specific infliximab concentrations in calibrator 1-6 and in control 1 and control 2.

Mouse-anti-TNF/recombinant TNF pre-coated microtiter plate

12 x 8 wells


ready for use

Calibrator 1 – 6

6 x 1 mL

black caps M2912

ready for use

Control 1

1 x 1 mL

clear cap M2913

ready for use; therapeutic range

Control 2

1 x 1 mL

clear cap M2914

ready for use; sub-therapeutic range

Human anti-infliximab HRP-conjugate 1 x 12.5 mL brown bottle M2915 dilute 1:20 in distilled water
Wash buffer stock solution

1 x 50 mL

white bottle M1805

ready for use

HPE dilution buffer 1 x 50 mL white bottle M2940 ready for use
TMB substrate solution 1 x 12.5 mL brown bottle M1821 ready for use
Stop solution 0,18 M H2SO4 1 x 13.0 mL white bottle M1823
Plate seals 10 x


The kit has been designed for professional use only, the user must be trained and familiar with ELISA test procedures.

Test procedure

Specimen collection and preparation
1. Trough samples must be used to measure the concentration of infliximab, thus samples must be taken within 24 hours BEFORE the drug is injected to make sure that the indicated expected levels reflect the trough level of the patient.
2. Only serum and EDTA plasma can be used in the assay.
3. Separate plasma or serum from the blood cells within 4 hours after collection and perform the analyses immediately. If testing of the samples is delayed, they can be stored at 2-8 °C for 72 hours. If samples are not analysed within 72 hours, the samples must be stored frozen, they can be stored at ≤ -18 °C for 12 months.
4. Aliquot samples to avoid freeze-thaw cycles.
5. Prior to the assay, frozen samples must be thawed at room temperature. Do not use 37 °C or 56 °C water baths for thawing. 6. Mix the samples just before preparing the dilutions.


Find out more information about the scientific background of the product.

van den Bemt B.J.F. (2008)

Annals of the Rheumatic Diseases.

View study

Aarden L. (2008)

Current Opinion in Immunology.

View study

de Vries M.K. (2007)

Annals of the Rheumatic Diseases.

View study

Wolbink G.J. (2006)

Arthritis & Rheumatology.

View study

Van der Bemt B.J.F. (2013)

British Journal of Clinical Pharmacology.

View study

Vande Casteele N. (2015)


View study

Partners Anti Body Chain

Are you interested in a product or do you have questions?

Fill in the information below.